Ozempic and Wegovy-maker Novo Nordisk will cut 9,000 jobs, or roughly 11.5% of its global workforce, as part of restructuring efforts. The Dutch pharma giant aims to save 8 billion Danish krone ($1.26 billion) annually after the layoffs. The firm also expects full-year operating profit growth of 4%–10%, while around 5,000 of these reductions are expected in Denmark.